Oncology
Tetrathiomolybdate abridges NFkappaB signals to halt cancer metastasis
Published in Gene Therapy Weekly, October 16th, 2003
"Tetrathiomolybdate (TM), a specific copper chelator, has been shown to be a potent antiangiogenic and antimetastatic compound possibly through suppression of the NFkappaB signaling cascade. To further delineate the molecular mechanism of the anticancer effect of TM, we investigated whether TM has antineoplastic activity in the setting of genetic NFkappaB inhibition. In this study, SUM149 inflammatory breast carcinoma cells were transfected with a dominant-negative IkappaBkappa (S32AS36A) expression vector," scientists in the United States reported.
"Similar to TM-treated SUM149...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-10-16)
More Articles from Gene Therapy Weekly
- Head and Neck Cancer
Liposomal conjugation improves adenoviral transduction of squamous cell cancer - Oncology
Nonradioactive iodide stimulates apoptosis in genetically modified cancer cells - Endocrinology
Excess Bcl-2 production reverses programmed cell death in beta cells - Neuroscience
Gene-modified cells correct Parkinson-like disease in animal models - Oncology
Gene expression mechanisms enhance magnetic resonance images of prostate cancer - Orthopedics
Bone morphogenetic protein-4 gene therapy regenerates in vivo bone formation - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
